Ipamorelin is a secretagogue peptide. This means that it can play a part in the regulation and control of body weight as well as energy homeostasis in animal test subjects. It is comparable to the peptide GHRP-6, with one of the primary differences being that Ipamorelin is a penta-peptide and not a hexa-peptide, meaning that the peptide consists of five sides instead of six. It is considered to be an agonist; that is, it has the ability to bind to certain receptors of a cell and trigger a cellular response. The peptide is available for purchase of the expressed, exclusive use of scientific study and research on animal test subjects. It is administered to animal test subjects through subcutaneous injection as part of ongoing scientific study conducted to research its properties and operational mechanisms.
According to scientific research conducted on animal test subjects, Iparmorelin’s main function is to stimulate the pituitary gland. This is the pea-sized gland found at the brain’s base, and it is responsible for regulating an organism’s endocrine-based functionality. The various functions linked to the gland include:
- Regulation of thyroid gland function
- Pain relief
- Regulation of temperature
- Regulation of blood pressure
- Regulation of bodily growth
Part of Ipamorelin’s mechanics is that it stimulates the production of growth-related secretions from the pituitary gland of animal test subjects. At the same time, Ipamorelin has been determined through scientific research conducted on animal test subjects to block the production of somatostatin; a peptide that is primarily responsible for blocking the release of growth secretions. Additionally, the peptide has been shown to elevate the production of IGF-1. This secretion, also known as Insulin-Like Growth Factor 1 or somatomedin C, is comparable to the molecular build of insulin which is expressed in animal test subjects as an endocrine secretion, which through scientific research has determined to be the main anabolic mechanism of action for secretions related to growth. This segment of the peptide’s functionality makes it akin to the operational tendencies of GHRP-6. However, unlike GHRP-6, Ipamorelin functions to bind to major control points of gastric, appetite, and growth motility. In other words, scientific research on animal test subjects have determined that the peptide does not evoke an elevation in hunger levels, which has been determined to be an effect of GHRP-6.
Additionally, scientific studies on animal test subjects show that Ipamorelin does not significantly elevate the production levels of cortisol; the hormone found in animal test subjects that raise blood sugar through the methodology of gluconeogenesis. It also does not significantly elevate the production levels of prolactin; the hormone that plays a significant role in regulating the immune system of animal test subjects, primarily as it relates to lactation.
Theoretical Benefits of Ipamorelin
Scientific research that has been conducted on animal test subjects has determined a host of different theoretical benefits which have been linked to Ipamorelin. These theoretical benefits include:
- Rejuvenation of joints
- Strengthening of connective tissue
- Strengthening of joints
- Increased fat loss
- Improved skin tone
- Strengthening of bone mass
These kinds of positive benefits have led some scientific studies to determine that the peptide could be beneficial in conjunction with the slowing down of the aging process.
Potentially Negative Side Effects of Ipamorelin
According to scientific research that has been conducted on animal test subjects, the potentially negative side effects of Ipamorelin has been determined to be minimal. These negative side effects have chiefly been known to consist of headaches and head rushes (that is, a feeling of light-headedness). The research that has been conducted on animal test subjects has determined that these side effects are generally mild in their nature. Furthermore, the list of negative side effects has been determined to be much shorter than the list of negative side effects that are typically tied to the peptide GHRP-6.
For Clinical Research Only
Although scientific study conducted on animal test subjects have determined an outline relating to Ipamorelin’s functionality and operational mechanisms, it should be noted that work with the peptide is still currently in the research stage. Any positive benefits or negative side effects that have been documented through scientific research on animal test subjects is still a product of ongoing, and not conclusive, research. As such, any matters of purchase relating to this peptide must exclusively be contained to scientific research, and any study should be contained to the confines of a strictly controlled environment such as a laboratory or a medical research facility.